AUG 17, 2026 · PHASE 1/2 TRIAL
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
ClinicalTrials.gov
This is a first-in-human Phase 1/2 study still in recruitment with no results posted; it aims to establish safety, pharmacokinetics, and preliminary efficacy of a novel antibody-drug conjugate.
Reported
Planned enrollment250
Primary outcome measureDetermination of MTD, from enrollment until…
Dosing intervalEvery 3 weeks